Suministro de Toxina Botulínica (DOE) tipo A
TED · 678863-2026Award notice · modificationawardedNo deadline given
Buyer
NameOSAKIDETZA - Servicio Vasco de Salud - Organización Central
CountryES
Published2026-10-02
Deadline—
Value
Estimated—
Awarded€2,175,312 · 2,175,311.6 EUR
WinnerIPSEN PHARMA, S.A. | MERZ THERAPEUTICS IBERIA SL | ABBVIE SPAIN, S.L.
Who already wins at this buyer
Firms with recorded awards from OSAKIDETZA - Servicio Vasco de Salud - Organización Central in this tender’s CPV categories — the incumbents you are bidding against.
| Firm | Wins | Awarded | Last win |
|---|---|---|---|
| ASTRAZENECA FARMACEUTICA SPAIN, S.A. | 6 | €14,614,191 | 2026-10-22 |
| PFIZER, S.L. | 5 | €67,637,810 | 2026-10-09 |
| EDWARDS LIFESCIENCIES, S.L. | ABBOTT MEDICAL ESPAÑA SA | MEDTRONIC IBÉRICA, S.A. | BOSTON SCIENTIFIC IBÉRICA, S.A. | MERCÉ V. ELECTROMEDICINA, S.L. | PALEX MEDICAL | SAGITTAE MEDICAL S.L | SERMEBI 97 SL | 5 | €40,141,054 | 2026-09-18 |
| TAKEDA FARMACÉUTICA ESPAÑA, S.A. | 5 | €10,796,370 | 2026-10-16 |
| ROCHE FARMA, S.A. UNIPERSONAL | 4 | €130,837,823 | 2026-09-08 |
CPV codes
33600000 Medical equipment & pharmaceuticalsDescription
Suministro de Toxina Botulínica (DOE) tipo A
Similar tenders
Closest by meaning — across languages, via embeddings.
| Published | Title | Buyer | Match |
|---|---|---|---|
| 2026-09-07 | Suministro de Tocilizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 98% |
| 2026-07-15 | Suministro de Abrocitinib (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 97% |
| 2026-09-25 | Suministro de concizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 97% |
| 2026-05-29 | Suministro de ácido carglúmico (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 97% |
| 2026-06-11 | Suministro de Avelumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 97% |
| 2026-06-04 | Suministro de Risankizumab (DOE) | OSAKIDETZA - Servicio Vasco de Salud - Organización Central ES | 97% |